BridgeBio Pharma (NASDAQ: BBIO) director exercises options, sells 148,589 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. director Jennifer E. Cook reported an option exercise-and-sale sequence in common stock. On July 9, 2026, she exercised stock options covering 148,589 shares at exercise prices of $8.45, $16.75, and $29.00 per share, then sold 148,589 shares of common stock in open-market transactions at prices of $90.00 and $84.00 per share. The sales were effected pursuant to a Rule 10b5-1 sales plan adopted on March 16, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 148,589 shares ($13,156,008)
Net Sell
8 txns
Insider
Cook Jennifer E.
Role
Director
Sold
148,589 shs ($13.16M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 19,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 112,422 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 17,167 | $0.00 | -- |
| Exercise | Common Stock | 19,000 | $8.45 | $161K |
| Exercise | Common Stock | 112,422 | $29.00 | $3.26M |
| Exercise | Common Stock | 17,167 | $16.75 | $288K |
| Sale | Common Stock | 36,167 | $84.00 | $3.04M |
| Sale | Common Stock | 112,422 | $90.00 | $10.12M |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 27,383 shares (Direct)
Footnotes (1)
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Key Figures
Shares sold: 148,589 shares
Sale prices: $90.00 and $84.00 per share
Shares exercised: 148,589 shares
+3 more
6 metrics
Shares sold
148,589 shares
Total common shares sold in open-market transactions on July 9, 2026
Sale prices
$90.00 and $84.00 per share
Prices for the reported open-market sales of common stock
Shares exercised
148,589 shares
Total common shares acquired through option exercises on July 9, 2026
Option exercise price
$8.45 per share
Exercise price for one stock option tranche converted into common stock
Option exercise price
$16.75 per share
Exercise price for a second stock option tranche converted into common stock
Option exercise price
$29.00 per share
Exercise price for a third stock option tranche converted into common stock
Key Terms
Rule 10b5-1 sales plan, Stock Option (Right to Buy), derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 sales plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did BridgeBio Pharma (BBIO) director Jennifer E. Cook report in this Form 4?
Jennifer E. Cook reported exercising stock options for 148,589 shares of BridgeBio Pharma common stock and selling 148,589 shares in open-market transactions at $90.00 and $84.00 per share on July 9, 2026.
What stock options did Jennifer E. Cook exercise in BridgeBio Pharma (BBIO)?
She exercised stock options for a total of 148,589 shares of BridgeBio Pharma common stock at exercise prices of $8.45, $16.75, and $29.00 per share, converting derivative securities into common shares.
Does the Form 4 show net buying or selling by Jennifer E. Cook in BBIO?
The Form 4 reflects net selling activity. Cook exercised options for 148,589 shares and sold 148,589 shares of BridgeBio Pharma common stock, resulting in a net-sell share balance for the reported transactions.
What types of securities are involved in Jennifer E. Cook’s BBIO Form 4 filing?
The filing involves BridgeBio Pharma common stock and stock options (right to buy), with the options exercised into common shares and then corresponding amounts of common stock sold in open-market transactions.